UPCC 16323: Neoadjuvant/Phase 1 Study of CD40 Agonist (LVGN7409) and PD-1 Inhibitor (LVGN3616) in Patients with Resectable HPV-Negative Mucosal Head/Neck Squamous Cell Carcinoma (HNSCC)
Enrolling By Invitation
99 years and younger
All
Phase
N/A
20 participants needed
1 Location
Brief description of study
Please refer to Protocol Section 3 (Study Objectives and Endpoints). Please refer to Protocol Section 3 (Study Objectives and Endpoints). Please refer to Protocol Section 3 (Study Objectives and Endpoints).
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Medical Research
-
Age: - 99 Years
-
Gender: All
TBD
Updated on
01 Aug 2024.
Study ID: 855063
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com
